Boehringer Ingelheim
Veranderd: 21 dec 2011
Gepubliceerd: 13 jun 2011 00:00
Boehringer Ingelheim gebruikt het Quadia online video platform voor nascholingen, congresverslagen en peer reviews. De belangrijkste doelstelling is het verspreiden van kennis en informatie binnen internationale doelgroepen als medici en de pers. Boehringer Ingelheim werkt nauw samen met het Quadia Healthcare team om nieuwe content te ontwikkelen (lees meer hierover in de bijgesloten reference case).
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Boehringer Ingelheim is committed to develop a range of targeted therapies in areas of medical need, including various solid tumours and haematological cancers.
Ga naar Boehringer Ingelheim